SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is experiencing significant buzz following FDA approval for YARTEMLEA, its groundbreaking treatment for TA-TMA, which also includes pediatric use. The community is buzzing with excitement over its "first and only" approved status, anticipating a substantial re-rating and potential short squeeze, with many long-term holders eyeing significant upside and a possible buyout by NVO. Despite some discussions around potential profit-taking, a strong sense of long-term value and market opportunity prevails among investors.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA CRYPTO) is trending as a potentially undervalued infrastructure play, with its compliance-first architecture and impressive throughput of over 11 million transactions per second positioning it as critical global financial plumbing. The community is actively discussing its live integration with Bridge, a Stripe-owned fiat anchor, enabling seamless transfers between traditional banking and crypto for institutional flows. This makes KTA an early-stage opportunity for those seeking exposure to the future of financial systems.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

Yee Token ($YEE) is generating significant buzz and upward momentum, with the community actively celebrating notable price appreciation and continuous gains. Enthusiasts are rallying around an "unfolding prophecy" and "ETH season" narrative, firmly positioning $YEE as a compelling, generational meme coin to "study" and accumulate during market pullbacks.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending due to groundbreaking preliminary data from its FLAMINGO-01 trial, showing an impressive approximately 80% reduction in breast cancer recurrence rates, a development the community views as a significant de-risking event for the immunotherapy. This positive clinical update, coupled with an exceptionally high cost-to-borrow rate and a very low share float, is fueling intense investor speculation about an imminent short squeeze and potential strategic partnerships, as insiders continue to demonstrate strong conviction through share accumulation.

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending amid strong community buzz, driven by discussions surrounding its notably low public float and the potential for a short squeeze following recent significant market activity. Many are highlighting that a substantial portion of shares are locked up for months, suggesting minimal dilution risk and drawing comparisons to other volatile low-float runners within the active Robotics/AI sector. Traders are actively debating market manipulation narratives alongside calls to hold for further upward momentum, especially as attention focuses on warrant exercisability in the coming weeks.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending after Apple CEO and board member Tim Cook's notable open-market purchase of its shares, which many in the community are interpreting as a strong vote of confidence. This insider buying has ignited conversations about a potential turnaround and short squeeze for the stock, which has recently faced headwinds from China sales and tariff concerns.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is a top trending stock following the landmark FDA approval of its oral Wegovy pill, a major development set to revolutionize the weight-loss market by offering a convenient, needle-free treatment option. The community is buzzing with optimism, anticipating significant long-term growth and market share expansion for NVO in the rapidly expanding GLP-1 sector, despite competitive dynamics.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is trending after Sanofi's definitive agreement to acquire the company for $15.50 per share in cash, representing a significant premium. This move bolsters Sanofi's adult immunization portfolio with Dynavax's Heplisav-B and a promising shingles vaccine candidate. The community is actively debating the acquisition price, with many long-term shareholders expressing disappointment and some speculating on the possibility of a higher bid.

Frequency Electronics, Inc. engages in the design, development, and manufacture of precision time and frequency generation technology. It operates through the FEI-NY and FEI-Zyfer business segments. The FEI-NY segment provides precision time, frequency generation, and synchronization products and subsystems that are found on-board satellites, in ground-based communication stations, and imbedded in moving platforms. The FEI-Zyfer segment designs, develops, and manufactures products for precision time and frequency generation and synchronization, primarily incorporating GPS technology. The company was founded by Martin B. Bloch on August 25, 1961 and is headquartered in Uniondale, NY.

Frequency Electronics, Inc.

Frequency Electronics is a top discussion point following strong Q2 sales and a record backlog, with the CEO hinting at significant upcoming contracts in quantum sensing and defense. The community actively highlights its critical role in initiatives like the Golden Dome and its low float, driving bullish price expectations as an underfollowed gem.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals is trending following recent FDA approval of AQVESME for anemia in adults with alpha- or beta-thalassemia, marking it as the only approved therapy for this rare blood disorder. The community is expressing significant optimism, anticipating upward movement as this decision broadens the company's therapeutic offerings. This development is driving conversations around the stock's potential within the rare disease sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Jackson highlighted the rising origination, new capital flow, and the tailwinds that are helping the firm propel forward.</li><li>He stated that the company is well-positioned to address any uncertainties arising from the current environment.</li><li>The CEO noted that, given the company's efficiency and profitability, raising the guidance was a natural outcome.</li></ul>Abacus Global Management Inc. (ABL) recently reported an upbeat third quarter, with the results surpassing Wall Street expectations for the tenth consecutive quarter.Abacus Global reported earnings per share (EPS) of $0.24 in the third quarter (Q3), compared to an estimated EPS of $0.18, according to Stocktwits data. Its revenue stood at $63 million during the quarter, compared to a Street estimate of $50.2 million.<a href="https://stocktwits.com/symbol/ABL">Abacus Global shares</a> were up more than 4% in Monday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory at the time of writing.Stocktwits caught up with CEO Jay Jackson to understand what drove Abacus Global’s Q3 performance, and what lies ahead for the company.We would like to start with your thoughts on Q3 performance, as well as the longevity of the product in the Middle East.We had an incredibly productive Q3. That was our 10th consecutive quarter in a row where we had exceeded earnings expectations related to consensus. So, we're incredibly proud of that. What's interesting about that statistic is that, actually, six of those quarters we beat earnings estimates by over 30%, including Q3, primarily driven by our continued efforts to expand our message and reach new investors and policyholders.We're seeing our origination tick up. We're also seeing new capital coming into the asset. But most importantly, from a market perspective, I think we've also got some wind at our backs. Specifically, around the premise that people are seeking uncorrelated assets. There's almost a flight to safety and other kinds of assets. And this is an uncorrelated yielding product. And now we're starting to see investors really lean into this asset class. I think that's also helping drive our success right now. And we foresee this continuing.The company's business is evolving slightly from a niche life settlement player to the broader alternative asset management and wealth management segments. What’s driving this transformation?I think that was always kind of the natural evolution of our company, which is that we provide a very distinct service initially to policyholders, and that service is helping them monetize or understand the liquidity in their life insurance policy through its current market value.If the number one fear in retirement is running out of money, wouldn't you like to know how long you're going to be in retirement? Right? So, our underwriting is being applied in multiple ways. But in addition to that, institutional asset management firms, banks, etc., have been looking for this kind of yield.How do you plan to sustain this momentum?One, there's a huge amount of excitement around investing in uncorrelated assets. Just look at the price of gold. Gold's what, $4,000 now, right? You could look at alternative assets, whether it's private credit, [they’ve] raised billions. So I think that there's a lot of room to go here, and quite frankly, we're just scratching the surface. Our expectation is that there will be billions and billions of dollars in assets under management with our firm.We expect people to continue seeking this kind of asset, and don't forget that we're the originator. We're the market maker of that asset. So, they have to come to us, and now they're investing directly.Amid this evolution, the company announced a dividend and share buyback. How do you strike a balance between distributing capital and reinvesting in the company's future growth?We felt it was the right time, and the reason was that as we've seen our business evolve, we wanted to reward our shareholders appropriately. If you look at the formula that we put out in our press release, we actually put out a pretty conservative dividend. It's only a little over 20% of our adjusted net income.We have excess capital to deploy, and we took that excess capital and capitalized our shareholders through our recurring revenues. We think that's the right way to conduct ourselves as an alternative asset manager and should be rewarding our shareholders on an annual basis.Regarding the disconnect in valuation, what do you think retail investors and institutions are missing out on?It’s really an education issue, and it's not just institutions; it's retail, it's across the board in understanding that first and foremost, life insurance is an asset. People treat it as something that they never want to use or as a piece of debt. They don't see it, oh, this is just like any other form of private credit. And so that's why that disconnect exists.That education has to start at the core level, and that takes time. We've spent the last three years doing that, and that message is really starting to resonate.We're right at the precipice of what I think is a breakout. And it's coming from institutions, which are really starting to get this business, retail investors who are kind of nodding their heads and saying, "Oh, I really do get this now."What was the driving factor behind raising FY25 net income guidance?I would say the driving factor for us continuing to increase our guidance is predominantly driven by market forces, in a sense. We are [also] becoming more efficient in our underlying business.We run an incredibly efficient and profitable business. And so I think when you look at the raise on our guidance, that was a natural outcome.The average realized gain in Q3 was around 37%, up from 26% in Q2. Is this due to efficiency, or is there another factor driving it? Do you think this is sustainable?I think it's definitely driven by efficiency, but you'll see it vary quarter to quarter. I mean, if you go back a few more quarters, you'll see that number hover between the 20% to 25% range. And I think that this was an exceptional quarter in Q3, partly driven by our efficiencies, partly driven by market factors.There's a lot of uncertainty regarding rates, and people are still not sure if there will be a hard landing or a recession. How are you going to tackle this sort of uncertainty going forward?We're in a great spot for that kind of uncertainty. I mean, consider the asset. We would benefit in two ways. Actually, both sides of our transaction.One, if you're a policyholder and we're in a recession, and you're seeking liquidity, which means you'll look to places that you may not have considered in the past, such as your life insurance policy, to seek liquidity where you haven't done so before. Originations will more than likely tick up during a recession.The second piece that investors seek during a recessionary environment, like a volatile market or a pullback, is uncorrelated assets.What makes you distinct from your competitors, and can you explain the competitive advantage you have?We're the only public company in our entire industry, and that gives us a significant advantage from both a cost of capital and an efficiency perspective. You know we're always driving our growth, because as a public company, you know you're reporting every quarter, and so being innovative is super important.The interview has been edited for clarity and length.<a href="https://stocktwits.com/symbol/ABL">ABL stock</a> is down 18% year-to-date and 27% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-rise-senate-votes-to-end-government-shutdown/cLPcKrVRE22">Dow Futures Rise As Senate Votes To End Government Shutdown: MTSR, VSAT, RUM, TSM Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retirement planning representational image

Exclusive: Abacus Global CEO Jay Jackson Eyes Billions In AUM, Explains How The Company Plans To Bridge The Valuation Disconnect

In an exclusive conversation with Stocktwits, Jackson lays out what drove Abacus Global’s performance, the market opportunity ahead, and what makes the company distinct from its competitors.

ABCGF
Abacus Group - Stapled (Unit, Ordinary Share) - New

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ABCGF News

ABCGFAbacus Group - Stapled (Unit, Ordinary Share) - New